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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S472Following a 3 bi-weekly injection regimen there was a 28% and a 37%
reduction in thewidth of signiﬁcant tibial lesions, respectively, for 10 mg
and 30 mg doses. This partial loss in efﬁcacy by conducting 3 bi-weekly
treatments rather than 6 weekly treatments was partially compensated
for by increasing the 3 injection regimen rhGDF5 dose from 30 mg to 100
mg, which reduced lesion width by 41%. In Study 3, a single rhGDF5
injection on day 21 reduced the width of signiﬁcant tibial lesions
compared with vehicle controls by 13% and 19% for a 30 mg and 100 mg
dose respectively. The 2 injection regimen administered on days 21 and
35 post MMT reduced tibial lesion width by 18% and 28%, and the 3
injection regimen reduced these lesions by 27% and 43%. After
accounting for a modest vehicle effect, the level of Day 63 cartilage
degeneration observed with 3 biweekly injections of rhGDF5 (30 or 100
mg) was signiﬁcantly less than the untreated controls at day 21. This is
indicative of disease arrest and cartilage regeneration with repeated
injections of higher doses of rhGDF5.
Conclusions: Intra-articular delivery of rhGDF5 signiﬁcantly protected
the knee joint from MMT-induced OA disease in a dose and admin-
istration regimen dependent manner. Our data indicate that even a
single injection of 100 mg rhGDF5 has signiﬁcant therapeutic beneﬁt.
Additionally, rhGDF5 is able to arrest disease progression in a ther-
apeutic modality with as few as 2 bi-weekly injections. Moreover, 3 bi-
weekly injections of 100 mg rhGDF5 was able to stimulate cartilage
regeneration in the MMT model. Collectively, these results clearly
demonstrate the potential of rhGDF5 supplementation as a targeted
therapeutic approach for treating OA.
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MAGNETIC RESONANCE IMAGING STRUCTURAL PARAMETERS DO
NOT PREDICT RESPONSE TO INTRA-ARTICULAR STEROID THERAPY
IN KNEE OA
N. Maricar y, M.J. Parkes y, D.T. Felson y,z, T.F. Cootes y, A.D. Gait y,
E.J. Marjanovic y, D. Bailey x, C.E. Hutchinson x, T.W. O’Neill y. y The Univ. of
Manchester, Manchester, United Kingdom; zBoston Univ., Boston, MA,
USA; x The Univ. of Warwick, Coventry, United Kingdom
Purpose: Intra-articular steroid therapy is widely used in the man-
agement of osteoarthritis (OA) of the knee. Meta-analyses suggest
treatment is linked with a signiﬁcant reduction in pain at least in the
short term (< 3weeks). Steroids havemarked anti-inﬂammatory effects
and it is thought that their analgesic effect may be related in part to
this.Some knees with OA have little if any synovitis whereas in others,
synovitis, assessed as synovial volume, is similar to rheumatoid
arthritis. It is not known, however, whether response to therapy is
inﬂuenced by the degree of synovitis present nor of the presence of
bonemarrow lesions (BMLs), lesions also related to pain. The aim of this
analysis was to determine the inﬂuence of synovitis, as assessed by
synovial volume using magnetic resonance imaging (MRI), and also the
summed score of BMLs, on the symptomatic response to treatment with
intra-articular steroid therapy.
Methods: Men and women aged 40 years and older with painful knee
OA who met the American College of Rheumatology (ACR) criteria for
the disease, were recruited for participation in an ongoing open label
clinical trial of intra-articular steroid therapy. Subjects who took part in
the study had signiﬁcant knee pain and knee OA (Kellgren-Lawrence
grade 2 or more). At baseline they completed questionnaires about their
symptoms including the Knee Injury and Osteoarthritis Outcome Score
(KOOS) (0-100) with the lower scores indicating greater pain and also a
VAS (0-10) for pain during a nominated activity (VASnA) with higher
scores indicating greater pain. They subsequently had a gadoli-
nium(Gd)-enhanced MRI scan immediately prior to having an intra-
articular steroid injection (depomedrone 80 mg) with repeat ques-
tionnaires and Gd-enhanced MRI scan at follow-up visit usually within
a 2 week period. To assess synovial tissue volume, sagittal (T1W Fat
Suppressed images: TR 500ms, TE 17ms; FoV 15.9 x 15.9cm; slice
thickness 3mm) scans were obtained. Manual segmentation of the
synovial tissue layer was performed on the post-contrast knee image by
a single observer. Using computer image analysis we excluded cartilage
within the segmented space, by thresholding in the associated sagittal
(3D WATSc: TR 20ms, TE 7.7ms, FoV 15cm, 288x288) scan. The rest of
the segmented space is assumed to be a mixture of ﬂuid and synovial
tissue. We calculated the proportion of synovial tissue in every voxel
and summarized these across voxels to compute a volume of synovium.
BMLs were assessed semi-quantitatively by an experienced MSK radi-
ologist using the WORMS method (range of possible scores 0-45) andthis represented the BML score. In the analysis we looked whether the
baseline structural parameters were associated with a change in both
KOOS-pain and also VASnA.
Results: We studied 100 participants of mean age 62.0 years (SD 10.4
years) and of whom 48were female. Themedian time between baseline
and follow-up scan was 8 days (IQR 7 to 14 days). The mean synovial
tissue volume at baseline was 10,033mm3 (SD 6,495mm3), and mean
total BML score 8 (SD 5.0). Overall, pain signiﬁcantly improved fol-
lowing steroid injection as indicated by an increase in KOOS (mean
change at follow-up ¼ 22.2 points; 95% CI 18.0 to 26.4; p < 0.001) and a
reduction in VASnA (mean change at follow-up ¼ -3.1cm; 95% CI -3.7
cm to -2.5 cm; p< 0.001). Neither synovial volume (r¼ 0.026; p¼ 0.80)
nor BML score at baseline (r ¼ -0.037; p ¼ 0.72) were associated with
the observed change in KOOS-pain. Similarly neither synovial volume (r
¼ 0.064; p ¼ 0.55) nor BML score at baseline (r ¼ 0.098; p ¼ 0.37) were
associated with a change in VASnA. Overall, based on the OARSI criteria
there were 67 responders and 33 non-responders. Baseline synovial
tissue volume did not differ in those who did, compared to those who
did not, subsequently respond (mean difference ¼ -76mm3; 95% CI
-2831mm3 to 2679mm3; p ¼ 0.96). Similarly, BML score did not differ
between those who subsequently did, compared to those who did not,
respond (mean difference ¼ -0.41; 95% CI -2.53 to 1.71; p ¼ 0.70).
Conclusions: Neither synovitis nor BML score predict response to intra-
articular steroid injection in patients with symptomatic knee OA.
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ELECTROSTATIC INTERACTIONS ENABLE RAPID PENETRATION,
ENHANCED UPTAKE & RETENTION OF INTRA-ARTICULAR INJECTED
AVIDIN IN RAT KNEE JOINTS
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Cambridge, MA, USA; zBIDMC, Harvard Med. Sch., Boston, MA, USA
Purpose: Osteoarthritis affects individual joints necessitating the need
for local therapy. Intra-articular (i.a.) injection of drugs remains inad-
equate due to rapid drug clearance from joint space. Local delivery into
cartilage is further complicated by its complex architecture of dense
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S473collagen matrix and proteoglycans. We previously showed that solutes
with diamw10 nm can slowly penetrate through the full thickness of
cartilage. But a highly positively charged globular protein, Avidin (Av)
(66 kDa,w7nm diam) rapidly penetrated into the deep zone of bovine
cartilage within 24 h, resulting in 400x higher uptake than its neutral
same-sized counterpart, NeutrAvidin (Nu). With the goal of using Av asa nanoparticle drug delivery carrier into cartilage, we injected it into
healthy rat knee joints to investigate uptake kinetics, tissue distribution,
and retention in vivo. We also studied the effects of Av on chondrocyte
viability, sGAG content, and PG biosynthesis rates using bovine cartilage
in vitro to determine the safe limit of Av for drug delivery.
Methods: Knee joints of healthy Fisher rats were injected with 50 ml of
50mM Av or Nu-Texas Red. Contralateral knees were used as controls.
Rats were sacriﬁced at 6 h, 1d, 4d, 7d, and 5 tissue types were extracted:
cartilage [C] (patellar groove, femoral condyle and tibial plateau);
menisci [M]; ligaments [L]; tendons (patellar [PT] and quadriceps [QT]);
and femoral bone. Samples were desorbed in 10x PBS for 48 h at 37C to
fully release Av into the bath. Solute concentration was measured and
normalized by tissue dry weight (Fig 1, Mean þ/- SD; N ¼ 6 rats per
condition). Av half-life was calculated in each tissue by ﬁtting expo-
nential decay curves to Fig 1 data, and then plotted versus tissue sGAG
content (measured via DMMB, Fig 2, blue lines depict 95% conﬁdence).
Dose dependent Av biological response (in-vitro): Bovine cartilage disks
(3 x 1mm) were cultured with a one-time 48 h dose of Av (0, 100nM,
1mM, 100 mM) over 10 days. Upon termination of culture, disks were
stained with ﬂuorescein diacetate (green, for viable cells) and propi-
dium iodide (red, for dead cells, [Fig 3]). Samples were digested and
sGAG released to the medium and retained in cartilage was measured
via DMMB; proteoglycan and protein synthesis rates were measured 48
h before termination of cultures (via sulfate and proline radiolabel
incorporation respectively), and normalized to wet weight (Fig 4B-C).
Results: Av penetrated rapidly into all tissues within 6 h (Fig 1). Av
concentration in cartilage decreased to 10.3% and 4.1% of the 24 h value
by 4d and 7d respectively. Despite similar size, no Nu was present at 24
h in cartilage. A positive correlation (R2¼0.83) between Av half-life and
sGAG content in different knee tissues conﬁrmed effects of electrostatic
interactions (Fig 2). There was no effect of Av dose on cell viability in
bovine cartilage compared to untreated controls (Fig 3), and no sig-
niﬁcant difference in the cumulative sGAG loss to medium between the
untreated control,100nM and 1 mMAv treated conditions, while 100 mM
Av resulted in w2x higher sGAG loss compared to controls (Fig 4A).
There was no change in rates of protein or sGAG synthesis with
increasing Av dose.
Conclusions: Our results show that electrostatic interactions aug-
mented Av transport enabling distribution throughout the joint and
penetration into tissues before being cleared by lymphatics. Av was
retained inside rat joints for 7 days with a half-life of 29 h in cartilage,
whereas Nu exhibited complete clearance within 24 h of i.a. injection.
We previously reported >90% retention of Av in bovine cartilage (in
vitro) for at least 15 days. A drop in retention in vivo is expected because
of the presence of convective transport & lymphatics. The 4.1% retention
at 7d in rat studies is most likely due to 10x lower thickness of rat
cartilage compared to bovine. Since the diffusion-binding time constant
scales as the square of tissue thickness, Av transport out of rat cartilage
is expected to be w100x faster, explaining the shorter retention dura-
tion overall. A carrier like Av (safe dose <1 mM) can transport low MW
drugs like dexamethasone into cartilage at a fast rate, bind with neg-
atively charged groups in tissue, thereby creating a drug depot inside
cartilage
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DEVELOPMENT OF AN AGGRECAN MIMIC TO HALT OSTEOARTHRITIS
PROGRESSION
K. Stuart y, S. Sharma z, A. Panitch z. y Symic BioMed., San Francisco, CA,
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Purpose: Osteoarthritis (OA) progresses via a feed-forward cycle in
which inﬂammation leads to the up-regulation of catabolic enzymes
that cleave the extracellular matrix (ECM) components; the ECM frag-
ments further stimulate inﬂammation. The degradation of aggrecan is a
critical early event in OA due to aggrecan’s ability to protect other ECM
components from degradation and support the compressive strength of
cartilage. We have developed a class of ECM-targeting proteoglycan
mimics, and here characterize an aggrecan mimic (mAGC) in its ability
to replace the functions of native aggrecan and halt the progression
of OA.
Methods: We synthesized mAGC by ﬁrst oxidizing chondroitin-6-sul-
fate (CS) and then conjugating hyaluronic acid-binding peptide to the
CS backbone. Three sets of experiments were performed. First, aggrecan
was removed from bovine cartilage plugs followed by treatment with
mAGC. Compressive strength of the tissue was assessed, and gene
